#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Have we observed any changes in the epidemiology and management of chronic hepatitis B?


Authors: J. Stránský 1;  J. Kynčl 2
Authors‘ workplace: I. interní klinika FNKV a 3. LF UK, Praha Přednosta: prof. MUDr. Jiří Horák, CSc. 1;  Státní zdravotní ústav Praha Odbor epidemiologie infekčních nemocí Vedoucí: MUDr. Jitka Částková, CSc. 2
Published in: Prakt. Lék. 2009; 89(7): 357-360
Category: Reviews

Overview

A review of recent developments in the epidemiology and therapy of chronic hepatitis B with nucleoside and nucleotide analogues and suitable recommendations for treatment.

Key words:
chronic hepatitis B, analogues therapy.


Sources

1. Ganem, D., Prince, A.M. Hepatitis B virus infection – natural history and clinical consequences. N. Engl. J. Med. 2004, 350, p. 1118-1129.

2. Lavanchy, D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat. 2004, 11, p. 97-107.

3. Marcellin, P., Dusheiko, G., Zoulim, F. et al. EASL Clinical Practise Guidelines: management of chronic hepatitis B. J. Hepatol. 2009, 50, p. 227-242.

4. Hadziyannis S.J., Vassilopoulos, D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34, p. 617-624.

5. Funk, M.L., Rosenberg, D.M., Lok A.S. World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J. Viral Hepat. 2002, 9, p. 52-61.

6. Zarski, J.P., Marcellin, P., Leroy, V. et al. Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases. J. Hepatol. 2006, 45, p. 355-360.

7. Locarnini, S., McMillan, J., Bartholomeusz, A. The hepatitis B virus and common mutants. Sem. Liv. Dis. 2003, 23, p. 5-20.

8. Hoofnagle, J.H., Shafritz, D.A., Popper, H. Chronic type B hepatitis and the „healthy“ HBsAg carrier state. Hepatology 1987, 7, p. 758-763.

9. Fattovich, G. Natural history and prognosis of hepatitis B. Sem. Liv. Dis. 2003, 23, p. 47-58.

10. Perillo, R. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease, Gastroenterology 2001, 120, p. 1009-1022.

11. Lok, A., Heathcote, J., Hoofnagle, J. Management of hepatitis B 2000: summary of a workshop. Gastroenterology 2001, 120, p. 1828-1853.

12. Martinot-Peignoux, M., Boyer, N., Colombat, M. et al. Serum hepatitis B virus DNA levels and liver histology in inactive HBsAg carriers. J. Hepatol. 2002, 36, p. 543-546.

13. Seo, Y., Yoon, S., Truong, B.X. et al. Serum hepatitis B virus DNA levels differentiating inactive carriers from patients with chronic hepatitis B. Eur. J. Gastroenterol. Hepatol. 2005, 17, p. 753-757.

14. Kumar, M., Sarin, S.K., Hissr, S. et al. Virologic and histologic festures of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology 2008, 134, p. 1376-1384.

15. Tsang, F.S.Y., Trinh, H., Garcia, R.T. et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin. Gastroenterol. Hepatol. 2008, 8, p. 569-574.

16. Tanaka, Y., Esumi, M., Shikata, T. Persistence of hepatitis B virus DNA after serological clearance of hepatitis B virus. Liver 1990, 10, p. 6-10.

17. Loriot, M., Marcellin, P., Talbodec, N. et al. Demostration of hepatitis B DNA by polymerase chain reaction in the serum after spontaneous or therapeutically induced HBeAg to anti-HBe or HBsAg to anti-HBs seroconversion in patients with chronic hepatitis B. Hepatology 1992, 15, p. 32-36.

18. Arase, Y., Ikeda, K., Suzuki, F. et al. Long term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am. J. Med. 2006, 119, E9-E16.

19. Ahn, S.H., Park, Y.N., Park, J.Y. et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 2005, 42, p. 188-194.

20. Adachi, H., Kaneko, S., Matsushita, E., et al. Clearance of HBsAg in seven patients with chronic hepatitis B. Hepatology 1992, 16, p. 1334-1337.

21. Yuen, M.F., Yuan, H.J., Wong, D.K. et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut 2005, 54, p. 1610-1614.

22. Chen, C.J., Yang, H.I., Su, J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. J. Amer. Med. Assoc. 2006, 295, p. 65-73.

23. Yuen, M.F., Wong, D.K.H., Fung, J. et al. HBsAg seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology 2008, 135, p. 1192-1199.

24. Hoofnagle, J.H., Doo, E., Liang, T. J. et al. Management of hepatitis B: summary of a clinical research workshop. Hepatology 2007, 45, p. 1056-1075.

25. Dienstag, J.L., Schiff, E.R., Wright, T.L. et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N. Engl. J. Med. 1999, 341, p. 1256-1263.

26. Liaw, Y.F., Sung, J.J.Y., Chow, W.C. et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N. Engl. J. Med. 2004, 351, p. 1521-1531.

27. Liaw, Y.F., Leung, N., Guan, R. et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Internat. 2005, 25, p. 472-489.

28. Yuen, M.F., Seto, W.K., Chow, D.H. et al. Long-term lamivudine therapy reduces the risk of long-term complications of chronic hepatitis B infection even in patients without advanced disease. Antiviral Therapy 2007, 12, p. 1295-1303.

29. Marcellin, P., Lau, G. K.K., Bonino, F. et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2004, 351, p. 1206-1217.

30. Marcellin, P., Chang, T.T., Lim, S.G. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N. Engl. J. Med. 2003, 348, p. 808-816.

31. Hadziyannis, S., Tassopoulos, N.C., Heatcote, E.J. et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N. Engl. J. Med. 2003, 348, p. 800-807.

32. Chang, T.T., Gish, R.G., de Man, R. et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 2006, 354, p. 1001-1010.

33. Lai, C.L., Shouval, D., Lok, A.S. et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 2006, 354, p. 1011-1020.

34. Lai, C. L., Gane, E., Liaw, Y. F. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 2007, 357, p. 2576-2588.

35. Marcellin, P., Heathcote, E.J., Buti, M. et al. Tenofovir disoproxil fumarate versus adefovir for chronic hepatitis B. N. Engl. J. Med. 2008, 359, p. 2442-2455.

36. Dienstag, J.L. Drug therapy: hepatitis B virus infection. N. Engl. J. Med. 2008, 359, p. 1486-1500.

37. Dusheiko, G. A pill a day, or two, for hepatitis B ? Lancet 1999, 353, 1032-1033.

Labels
General practitioner for children and adolescents General practitioner for adults
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#